Parametric Portfolio Associates LLC Takes Position in TG Therapeutics, Inc. (TGTX)

Parametric Portfolio Associates LLC acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the first quarter, according to its most recent 13F filing with the SEC. The firm acquired 79,654 shares of the biopharmaceutical company’s stock, valued at approximately $928,000. Parametric Portfolio Associates LLC owned approximately 0.14% of TG Therapeutics as of its most recent filing with the SEC.

A number of other large investors have also recently modified their holdings of TGTX. Ameriprise Financial Inc. purchased a new stake in shares of TG Therapeutics during the first quarter worth approximately $1,291,000. Swiss National Bank raised its stake in shares of TG Therapeutics by 18.9% in the first quarter. Swiss National Bank now owns 79,200 shares of the biopharmaceutical company’s stock worth $923,000 after buying an additional 12,600 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of TG Therapeutics by 40.7% in the first quarter. Bank of New York Mellon Corp now owns 271,879 shares of the biopharmaceutical company’s stock worth $3,168,000 after buying an additional 78,644 shares in the last quarter. Jennison Associates LLC purchased a new stake in shares of TG Therapeutics during the first quarter worth approximately $16,034,000. Finally, North Star Investment Management Corp. raised its stake in shares of TG Therapeutics by 110.0% in the first quarter. North Star Investment Management Corp. now owns 21,000 shares of the biopharmaceutical company’s stock worth $245,000 after buying an additional 11,000 shares in the last quarter. Hedge funds and other institutional investors own 46.53% of the company’s stock.

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) traded down 1.36% during mid-day trading on Friday, hitting $10.85. The company’s stock had a trading volume of 889,366 shares. The stock has a 50-day moving average of $10.91 and a 200-day moving average of $10.23. TG Therapeutics, Inc. has a 12-month low of $4.10 and a 12-month high of $15.35. The company’s market cap is $676.06 million.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.01. TG Therapeutics had a negative return on equity of 154.02% and a negative net margin of 68,806.59%. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. On average, equities research analysts forecast that TG Therapeutics, Inc. will post ($1.84) EPS for the current year.

WARNING: This news story was first posted by BNB Daily and is owned by of BNB Daily. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/19/parametric-portfolio-associates-llc-takes-position-in-tg-therapeutics-inc-tgtx-updated-updated-updated.html.

A number of brokerages recently commented on TGTX. Zacks Investment Research lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. BidaskClub lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. FBR & Co restated a “buy” rating on shares of TG Therapeutics in a research report on Saturday, June 17th. Jefferies Group LLC restated a “buy” rating and issued a $23.00 price objective on shares of TG Therapeutics in a research report on Monday, June 5th. Finally, ValuEngine upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Two analysts have rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $23.67.

In related news, CFO Sean A. Power sold 59,976 shares of TG Therapeutics stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $11.09, for a total transaction of $665,133.84. Following the sale, the chief financial officer now directly owns 477,464 shares of the company’s stock, valued at $5,295,075.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 16.70% of the stock is owned by company insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply